top of page

About Us

Fulfilling the Boundless Potential of the Immune System

Vitalli Bio Logo

Vitalli Bio is on a mission to translate bold scientific innovation in immunology by developing novel therapies that unlock the power of the immune system to treat disease. 

An Aditum Bio portfolio company, Vitalli Bio was formed in May 2023 following the successful in-licensing of a highly selective dual inhibitor (renamed VIT-801) of Interleukin-2-Inducible T-Cell Kinase (ITK) and Bruton’s Tyrosine Kinase (BTK) from Daewoong Pharmaceutical Company, for the treatment of a broad range of immunological (autoimmune) disorders. We are advancing the clinical development of VIT-801 and are anticipating beginning the first in-human trials by the fourth quarter 2023.

Vitalli Bio Logo

Learn about the best-in-class potential of our lead product candidate. 

Leadership Anchor


Board & Scientific Advisors

bottom of page